NEW ORLEANS--(BUSINESS WIRE)-- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Lipocine Inc. (NasdaqCM: LPCN). On June 29, 2016, the Company revealed that the FDA had denied approval of the Company’s lead drug product candidate, TLANDO (“LPCN 1021”), a testosterone replacement therapy drug. According to the Complete Response Letter issued by the FDA, the denial was based on the determina...
NEW ORLEANS--(BUSINESS WIRE)-- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Lipocine Inc. (NasdaqCM: LPCN). On June 29, 2016, the Company revealed that the FDA had denied approval of the Company’s lead drug product candidate, TLANDO (“LPCN 1021”), a testosterone replacement therapy drug. According to the Complete Response Letter issued by the FDA, the denial was based on the determina...
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.